Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Nutex Health (NUTX) Shares Outstanding (Weighted Average) (2016 - 2026)

Nutex Health (NUTX) has disclosed Shares Outstanding (Weighted Average) for 17 consecutive years, with $7.0 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) rose 23.34% year-over-year to $7.0 million; the TTM value through Mar 2026 reached $7.0 million, up 23.34%, while the annual FY2025 figure was $144620.0, 30.25% down from the prior year.
  • Shares Outstanding (Weighted Average) hit $7.0 million in Q1 2026 for Nutex Health, up from $144620.0 in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $646.4 million in Q2 2022 and bottomed at $144620.0 in Q4 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $115.9 million, with a median of $5.0 million recorded in 2024.
  • Year-over-year, Shares Outstanding (Weighted Average) skyrocketed 3091.98% in 2022 and then plummeted 99.32% in 2023.
  • Nutex Health's Shares Outstanding (Weighted Average) stood at $4.2 million in 2022, then increased by 4.15% to $4.4 million in 2023, then plummeted by 95.3% to $207338.0 in 2024, then crashed by 30.25% to $144620.0 in 2025, then surged by 4733.24% to $7.0 million in 2026.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $7.0 million, $144620.0, and $6.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.